Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-08-18 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于公司2017年半年度主要经营数据的公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as an announcement regarding the company's 2017 half-year main operating data. It contains detailed financial data for the half-year period, including revenue, cost, and gross margin by business segment and product, as well as geographic revenue breakdown. The document is relatively short (2491 characters) and focuses on key operating data rather than full financial statements or comprehensive analysis. It does not present a full interim report with detailed financial statements but rather a summary of main operating data for the half-year period. This fits the definition of an Interim / Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year (half-year). H1 2017
2017-08-18 Chinese
关于使用募集资金置换变更后募投项目“对昆药集团医药商业有限公司增资项目”预先已投入自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in a changed fundraising project. It details the background, investment projects, amounts, approvals by the board, and opinions from auditors, sponsors, independent directors, and the supervisory board. The document is a formal disclosure about the company's capital management and fundraising fund usage, specifically about replacing self-raised funds with raised funds. It does not contain financial statements or comprehensive financial performance data, nor is it a report or presentation. It is a regulatory announcement about capital use and compliance with fundraising regulations. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3651 characters, which is consistent with an announcement rather than a full report.
2017-08-18 Chinese
八届十九次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of Kunming Pharmaceutical Group Co., Ltd. regarding resolutions passed at the 19th meeting of the 8th supervisory board. It includes approval of the 2017 half-year report and related audit opinions, as well as approvals related to fundraising and capital use. The document is short (1148 characters) and primarily announces the resolutions and opinions rather than containing the full half-year report or detailed financial statements. It references other announcements and reports by their document numbers but does not include the full reports themselves. Therefore, this document is an announcement of supervisory board resolutions and opinions related to the interim report and fundraising, not the interim report itself. Given the nature and length, it fits best as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Capital/Financing Update (CAP).
2017-08-18 Chinese
公司债券募集资金管理办法
Governance Information Classification · 95% confidence The document is titled '昆药集团股份有限公司 公司债券募集资金管理办法' which translates to 'Kunming Pharmaceutical Group Co., Ltd. Company Bond Fundraising Management Measures.' It outlines rules and procedures for the management and use of funds raised through company bonds, including storage, usage restrictions, approval processes, and oversight by the board and supervisory committee. The content is regulatory and governance-related, focusing on internal rules for managing bond proceeds rather than financial results, capital changes, or announcements. It does not contain financial statements or earnings data, nor is it an announcement or certification. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2017-08-18 Chinese
关于公司会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy by the company Kunming Pharmaceutical Group Co., Ltd. It discusses the adoption of a revised accounting standard issued by the Ministry of Finance of China related to government grants. The document explains the nature of the change, its impact on financial statement presentation, and includes opinions from the board, independent directors, and the supervisory board. The document length is 1997 characters, which is relatively short and the content is focused on announcing and explaining the accounting policy change rather than presenting full financial statements or detailed financial analysis. It does not contain actual financial statements or comprehensive financial data typical of an Interim/Quarterly Report or Annual Report. It is not a certification letter or a regulatory compliance filing. Therefore, this document fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement about accounting policy changes that do not constitute a full financial report.
2017-08-18 Chinese
2017年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2017 年半年度报告' which translates to '2017 Semi-Annual Report'. It contains detailed financial data including revenue, profit, cash flow, assets, liabilities, and other financial metrics for the first half of 2017. The document includes sections such as company overview, business summary, management discussion and analysis, financial statements, and notes. It explicitly states it is a half-year report and includes comprehensive financial statements and analysis for the period January to June 2017. The length of the document (15,000 characters) and the detailed financial content confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-18 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.